Prabhu Roshan S, Corso Christopher D, Ward Matthew C, Heinzerling John H, Dhakal Reshika, Buchwald Zachary S, Patel Kirtesh R, Asher Anthony L, Sumrall Ashley L, Burri Stuart H
Levine Cancer Institute, Atrium Health, Charlotte, NC.
Southeast Radiation Oncology Group, Charlotte, NC.
Neurooncol Pract. 2020 Jul;7(4):391-399. doi: 10.1093/nop/npz070. Epub 2019 Dec 19.
Adult intracranial ependymoma is rare, and the role for adjuvant radiotherapy (RT) is not well defined.
We used the National Cancer Database (NCDB) to select adults (age ≥ 22 years) with grade 2 to 3 intracranial ependymoma status postresection between 2004 and 2015 and treated with adjuvant RT vs observation. Four cohorts were generated: (1) all patients, (2) grade 2 only, (3) grade 2 status post-subtotal resection only, (4) and grade 3 only. The association between adjuvant RT use and overall survival (OS) was assessed using multivariate Cox and propensity score matched analyses.
A total of 1787 patients were included in cohort 1, of which 856 patients (48%) received adjuvant RT and 931 (52%) were observed. Approximately two-thirds of tumors were supratentorial and 80% were grade 2. Cohorts 2, 3, and 4 included 1471, 345, and 316 patients, respectively. There was no significant association between adjuvant RT use and OS in multivariate or propensity score matched analysis in any of the cohorts. Older age, male sex, urban location, higher comorbidity score, earlier year of diagnosis, and grade 3 were associated with increased risk of death.
This large NCDB study did not demonstrate a significant association between adjuvant RT use and OS for adults with intracranial ependymoma, including for patients with grade 2 ependymoma status post-subtotal resection. The conflicting results regarding the efficacy of adjuvant RT in this patient population highlight the need for high-quality studies to guide therapy recommendations in adult ependymoma.
成人颅内室管膜瘤较为罕见,辅助放疗(RT)的作用尚未明确界定。
我们利用国家癌症数据库(NCDB)选取了2004年至2015年间接受手术切除的2至3级颅内室管膜瘤成年患者(年龄≥22岁),并对接受辅助放疗与观察等待的患者进行比较。共生成了四个队列:(1)所有患者;(2)仅2级患者;(3)仅次全切除术后的2级患者;(4)仅3级患者。采用多变量Cox分析和倾向评分匹配分析评估辅助放疗的使用与总生存期(OS)之间的关联。
队列1共纳入1787例患者,其中856例(48%)接受辅助放疗,931例(52%)接受观察等待。约三分之二的肿瘤位于幕上,80%为2级。队列2、3和4分别包括1471例、345例和316例患者。在任何队列的多变量或倾向评分匹配分析中,辅助放疗的使用与总生存期之间均无显著关联。年龄较大、男性、城市居住地、较高的合并症评分、较早的诊断年份以及3级与死亡风险增加相关。
这项大型NCDB研究未显示辅助放疗的使用与成人颅内室管膜瘤患者的总生存期之间存在显著关联,包括次全切除术后的2级室管膜瘤患者。关于该患者群体辅助放疗疗效的矛盾结果凸显了开展高质量研究以指导成人室管膜瘤治疗建议的必要性。